Within a week, this pharmaceutical company has signed two multi-billion-dollar cooperation projects

Since the beginning of this year, a large number of pharmaceutical companies have announced huge investments to cooperate with other companies to develop innovative drugs and even directly introduce innovative drugs
.
The industry believes that this is a reflection of pharmaceutical companies' continuous betting on innovative drugs in order to balance policies and the market
.
On October 15, Hansen Pharmaceuticals announced that it has entered into an exclusive license cooperation agreement with Silence Therapeutics plc
.
According to the announcement, Hansen Pharmaceuticals and Silence Therapeutics will use Silence Therpaeutics' exclusive mRNAi GOLD™ platform to jointly develop siRNA (short interfering RNA) targeting three targets
.
At that time, Hansen Pharmaceuticals will pay an advance payment of US$16 million, while Silence Therapeutics is expected to receive potential milestone payments of up to US$1.
3 billion including R&D, registration and commercialization milestones, as well as 10% based on product net sales.
Royalties up to 15%
.
Three days before the cooperation with Silence Therapeutics plc, Hansen Pharmaceuticals also entered into an exclusive license cooperation agreement ("License Agreement") with OliX Pharmaceuticals, Inc
.
.
According to the license agreement, OliX Pharmaceuticals will use GalNAc-asiRNA platform technology to discover lead drugs and ensure the development of drug candidates for targets in liver-related cardiovascular, metabolic and other diseases
.
It will receive an upfront payment of US$6.
5 million, as well as an amount of up to US$450 million based on important milestones and franchise license sharing
.
Hansen Pharmaceuticals will have the exclusive commercial rights of these therapies in China (including Hong Kong, Macau and Taiwan) (the "region")
.
According to the analysis, Hansen Pharmaceuticals has decided to invest more than 1.
75 billion US dollars in the interval of less than one week to develop two innovative drugs with foreign companies, which fully demonstrates Hansen Pharmaceuticals' strong independent research and development and international cooperation capabilities.
At the same time, it also reflects its emphasis on the development of innovative drugs and a clear R&D strategy
.
In fact, focusing on innovation is the core development driving force of Hansen Pharmaceuticals
.
In recent years, it has also continued to increase investment in research and development
.
It is reported that in addition to obtaining innovative drugs through the above methods, Hansen Pharmaceuticals has also established R&D centers in many places, and after establishing a complete R&D platform, it has also mastered a number of proprietary technologies
.
It is worth mentioning that on January 28 this year, the opening ceremony of the Biopharmaceutical R&D Center of Shanghai Hansen Biomedical Technology Co.
, Ltd.
, a subsidiary of Hansen Pharmaceuticals, was successfully held in the Jiechang Science and Technology Park in Pudong New District, Shanghai
.
The opening of this R&D center is of far-reaching significance to Hansen Pharmaceutical's further deepening of biopharmaceutical R&D and industrialization layout.
It also marks the company's bio-innovative drug R&D into a fast lane, opening a new chapter in innovative R&D and product structure transformation and upgrading
.
Data show that since this year, Hansen Pharmaceutical has submitted 12 applications for new drugs in Class 1, and products under research are constantly pouring into the review channel
.
In this context, the industry expects that with these R&D investments in the future, Hansen Pharmaceutical's product pipeline will become more abundant, and the company's performance will continue to improve, and its competitiveness will be further improved
.